Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immune Profiling of COVID-19-infected Patients Admitted to the Intensive Care Unit (ICU): the IMPROVISE Study

NCT04473131 is registered in ClinicalTrials.gov with Hamad Medical Corporation as lead sponsor.

NCT NCT04473131
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04473131 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immune Profiling of COVID-19-infected Patients Admitted to the Intensive Care Unit (ICU): the IMPROVISE Study
Lead sponsor
Hamad Medical Corporation
Phase
Observational
Overall status
Unknown status
Start date
April 27, 2020
Completion date
June 30, 2022
Enrollment
300 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19